JP2014530861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530861A5 JP2014530861A5 JP2014537216A JP2014537216A JP2014530861A5 JP 2014530861 A5 JP2014530861 A5 JP 2014530861A5 JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014530861 A5 JP2014530861 A5 JP 2014530861A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- kinase inhibitor
- tor kinase
- use according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549034P | 2011-10-19 | 2011-10-19 | |
| US61/549,034 | 2011-10-19 | ||
| US201261591401P | 2012-01-27 | 2012-01-27 | |
| US61/591,401 | 2012-01-27 | ||
| US201261647233P | 2012-05-15 | 2012-05-15 | |
| US61/647,233 | 2012-05-15 | ||
| US201261653436P | 2012-05-31 | 2012-05-31 | |
| US61/653,436 | 2012-05-31 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234951A Division JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530861A JP2014530861A (ja) | 2014-11-20 |
| JP2014530861A5 true JP2014530861A5 (enExample) | 2015-11-12 |
Family
ID=47116477
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537216A Pending JP2014530861A (ja) | 2011-10-19 | 2012-10-18 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2016234951A Active JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2018117932A Pending JP2018162286A (ja) | 2011-10-19 | 2018-06-21 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2020117028A Pending JP2020169203A (ja) | 2011-10-19 | 2020-07-07 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2021078559A Pending JP2021107461A (ja) | 2011-10-19 | 2021-05-06 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016234951A Active JP6360136B2 (ja) | 2011-10-19 | 2016-12-02 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2018117932A Pending JP2018162286A (ja) | 2011-10-19 | 2018-06-21 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2020117028A Pending JP2020169203A (ja) | 2011-10-19 | 2020-07-07 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
| JP2021078559A Pending JP2021107461A (ja) | 2011-10-19 | 2021-05-06 | Ｔｏｒキナーゼ阻害剤を用いたがんの処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9493466B2 (enExample) |
| EP (3) | EP3466423B1 (enExample) |
| JP (5) | JP2014530861A (enExample) |
| KR (1) | KR101978537B1 (enExample) |
| CN (2) | CN107157990B (enExample) |
| BR (1) | BR112014009755B1 (enExample) |
| CA (1) | CA2852921C (enExample) |
| EA (2) | EA034512B1 (enExample) |
| ES (2) | ES2751921T3 (enExample) |
| IL (3) | IL232128B (enExample) |
| IN (1) | IN2014CN02887A (enExample) |
| MX (4) | MX373925B (enExample) |
| MY (1) | MY183661A (enExample) |
| PH (1) | PH12014500869A1 (enExample) |
| SG (3) | SG10201912850WA (enExample) |
| TW (4) | TWI758746B (enExample) |
| UA (1) | UA115319C2 (enExample) |
| WO (1) | WO2013059396A2 (enExample) |
| ZA (2) | ZA201402771B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| JP2016505041A (ja) | 2013-01-16 | 2016-02-18 | シグナル ファーマシューティカルズ，エルエルシー | 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法 |
| AU2014223501A1 (en) * | 2013-02-28 | 2015-09-17 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| AU2014254053B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Treatment of cancer with Dihydropyrazino-Pyrazines |
| MX2015014455A (es) * | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. |
| US9359364B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one |
| US9474757B2 (en) * | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| SG10201801965RA (en) * | 2013-04-17 | 2018-04-27 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| WO2014172432A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| CA2908957C (en) * | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CA2908954C (en) * | 2013-04-17 | 2021-08-03 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| CN105407892B (zh) | 2013-05-29 | 2019-05-07 | 西格诺药品有限公司 | 一种化合物的药物组合物、其固体形式及它们的使用方法 |
| JP2016540726A (ja) * | 2013-10-04 | 2016-12-28 | シグナル ファーマシューティカルズ，エルエルシー | 遺伝子突然変異を特徴とする癌の予防又は治療におけるｔｏｒキナーゼ阻害剤 |
| ES2823756T3 (es) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| EP3169686A4 (en) | 2014-07-14 | 2018-01-24 | Signal Pharmaceuticals, LLC | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| SG11201804098TA (en) | 2015-11-20 | 2018-06-28 | Forma Therapeutics Inc | Purinones as ubiquitin-specific protease 1 inhibitors |
| US10765681B2 (en) | 2016-02-05 | 2020-09-08 | Academia Sinica | Purine compounds possessing anticancer activity |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| MA47079B1 (fr) | 2016-12-20 | 2021-05-31 | Astrazeneca Ab | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| CN111615556A (zh) * | 2017-11-01 | 2020-09-01 | 朱诺治疗学股份有限公司 | 产生t细胞组合物的方法 |
| KR102810102B1 (ko) | 2018-03-09 | 2025-05-21 | 리커리엄 아이피 홀딩스, 엘엘씨 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
| CN110526907B (zh) * | 2018-05-23 | 2021-04-23 | 四川大学 | 苯并噁嗪酮类衍生物及其应用 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| CN119431323A (zh) | 2019-07-31 | 2025-02-14 | 贝林格尔·英格海姆国际有限公司 | 作为cd38抑制剂的杂双环酰胺 |
| WO2021098813A1 (zh) * | 2019-11-22 | 2021-05-27 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物 |
| US20230026616A1 (en) * | 2019-11-25 | 2023-01-26 | Medshine Discovery Inc. | Pyrimidoimidazole compounds used as dna-pk inhibitors |
| TWI812223B (zh) * | 2021-05-19 | 2023-08-11 | 大陸商再鼎醫藥（上海）有限公司 | 雜環取代的嘌呤酮衍生物的鹽型及晶型 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE262026C (enExample) | ||||
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
| US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
| US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
| US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
| US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
| GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法 |
| DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
| TW274550B (enExample) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
| US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| US6093728A (en) | 1997-09-26 | 2000-07-25 | Asta Medica Aktiengesellschaft | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬 |
| JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
| JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体 |
| JP2004520299A (ja) | 2000-12-12 | 2004-07-08 | ニューロジェン・コーポレーション | スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類 |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| JP3876254B2 (ja) | 2001-09-04 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用 |
| EP1438048A1 (en) | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| RU2004135392A (ru) | 2002-05-06 | 2005-06-27 | Дженелэбс Текнолоджиз, Инк. (Us) | Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с |
| AU2003299531A1 (en) | 2002-08-05 | 2004-06-07 | University Of Massachusetts | Compounds for modulating rna interference |
| US7199119B2 (en) | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| RS52386B (sr) | 2003-02-26 | 2013-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg. | Dihidropteridinoni, postupak za njihovo pripremanje i njihova primena kao leka |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| AU2004232308A1 (en) * | 2003-04-23 | 2004-11-04 | Wyeth Holdings Corporation | PEG-wortmannin conjugates |
| FI2604620T4 (fi) | 2003-05-30 | 2024-09-11 | Gilead Pharmasset Llc | Modifioituja fluorinoituja nukleosidianalogeja |
| AU2004263080B2 (en) | 2003-06-26 | 2008-12-18 | Merck Sharp & Dohme Corp. | Benzodiazepine CGRP receptor antagonists |
| JP2008501707A (ja) | 2004-06-04 | 2008-01-24 | アイコス、コーポレーション | マスト細胞障害を処置するための方法 |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | ２－アリールプリン誘導体の製造方法 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AU2005289644A1 (en) * | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| ES2508766T3 (es) | 2004-10-29 | 2014-10-16 | Janssen R&D Ireland | Derivados de pirimidina bicíclicos que inhiben el VIH |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
| EP1828186A1 (en) | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| RU2405780C2 (ru) | 2005-02-16 | 2010-12-10 | Астразенека Аб | Химические соединения |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| CA2604161A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| EP2022498A3 (en) | 2005-11-21 | 2012-08-15 | Novartis AG | Neuroendocrine tumour treatment |
| US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| RS54542B1 (sr) * | 2006-08-02 | 2016-06-30 | Cytokinetics, Inc. | Određeni hemijski entiteti, kompozicije i metodi koji obuhvataju imidazopirimidine |
| US8268809B2 (en) | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| WO2008030744A2 (en) | 2006-09-05 | 2008-03-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-met and uses thereof |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| ZA200902384B (en) | 2006-10-19 | 2010-07-28 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| EP2457913B1 (en) * | 2006-10-19 | 2017-04-19 | Signal Pharmaceuticals, LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| AU2009314631B2 (en) | 2008-11-12 | 2014-07-31 | Takeda Pharmaceutical Company Limited | Pyrazinopyrazines and derivatives as kinase inhibitors |
| EP2379561B1 (en) * | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
| CA2778615C (en) | 2009-10-26 | 2019-04-23 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
| WO2011097333A1 (en) | 2010-02-03 | 2011-08-11 | Signal Pharmaceuticals, Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
| CN103857804A (zh) | 2011-08-03 | 2014-06-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
| SG11201402766UA (en) | 2011-12-02 | 2014-06-27 | Signal Pharm Llc | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-<i>B</i>]PYRAZIN-2(1<i>H</i>)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE |
-
2012
- 2012-10-18 CA CA2852921A patent/CA2852921C/en active Active
- 2012-10-18 SG SG10201912850WA patent/SG10201912850WA/en unknown
- 2012-10-18 EP EP18207204.1A patent/EP3466423B1/en active Active
- 2012-10-18 TW TW109119519A patent/TWI758746B/zh active
- 2012-10-18 IN IN2887CHN2014 patent/IN2014CN02887A/en unknown
- 2012-10-18 WO PCT/US2012/060723 patent/WO2013059396A2/en not_active Ceased
- 2012-10-18 TW TW101138515A patent/TWI629983B/zh active
- 2012-10-18 TW TW106118909A patent/TWI713752B/zh active
- 2012-10-18 MY MYPI2017000252A patent/MY183661A/en unknown
- 2012-10-18 PH PH1/2014/500869A patent/PH12014500869A1/en unknown
- 2012-10-18 EA EA201890768A patent/EA034512B1/ru not_active IP Right Cessation
- 2012-10-18 EP EP20152170.5A patent/EP3659599B1/en active Active
- 2012-10-18 SG SG11201401630SA patent/SG11201401630SA/en unknown
- 2012-10-18 US US13/654,441 patent/US9493466B2/en active Active
- 2012-10-18 MX MX2018008536A patent/MX373925B/es unknown
- 2012-10-18 BR BR112014009755-0A patent/BR112014009755B1/pt active IP Right Grant
- 2012-10-18 MX MX2014004775A patent/MX348566B/es active IP Right Grant
- 2012-10-18 UA UAA201405225A patent/UA115319C2/uk unknown
- 2012-10-18 JP JP2014537216A patent/JP2014530861A/ja active Pending
- 2012-10-18 ES ES12780374T patent/ES2751921T3/es active Active
- 2012-10-18 CN CN201710320646.1A patent/CN107157990B/zh active Active
- 2012-10-18 EA EA201490814A patent/EA030664B1/ru not_active IP Right Cessation
- 2012-10-18 CN CN201280062920.5A patent/CN103998036B/zh active Active
- 2012-10-18 ES ES18207204T patent/ES2894958T3/es active Active
- 2012-10-18 EP EP12780374.0A patent/EP2768500B1/en active Active
- 2012-10-18 MX MX2020004689A patent/MX384385B/es unknown
- 2012-10-18 MX MX2017002007A patent/MX357833B/es unknown
- 2012-10-18 KR KR1020147012908A patent/KR101978537B1/ko active Active
- 2012-10-18 TW TW106118908A patent/TWI708605B/zh active
- 2012-10-18 SG SG10201505102WA patent/SG10201505102WA/en unknown
-
2014
- 2014-04-13 IL IL232128A patent/IL232128B/en active IP Right Grant
- 2014-04-15 ZA ZA2014/02771A patent/ZA201402771B/en unknown
- 2014-10-24 ZA ZA2014/07793A patent/ZA201407793B/en unknown
-
2016
- 2016-09-27 US US15/277,285 patent/US9937170B2/en active Active
- 2016-12-02 JP JP2016234951A patent/JP6360136B2/ja active Active
-
2018
- 2018-01-10 IL IL256828A patent/IL256828B/en active IP Right Grant
- 2018-02-20 US US15/899,706 patent/US11166950B2/en active Active
- 2018-06-21 JP JP2018117932A patent/JP2018162286A/ja active Pending
-
2020
- 2020-07-07 JP JP2020117028A patent/JP2020169203A/ja active Pending
-
2021
- 2021-03-01 IL IL281180A patent/IL281180B2/en unknown
- 2021-05-06 JP JP2021078559A patent/JP2021107461A/ja active Pending
- 2021-10-07 US US17/496,433 patent/US20220273650A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530861A5 (enExample) | ||
| Park et al. | Multimodal management of muscle-invasive bladder cancer | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
| JP2017528475A5 (enExample) | ||
| JP2013508417A5 (enExample) | ||
| MY160399A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| WO2013093508A3 (en) | Wnt pathway inhibitors | |
| WO2012061557A3 (en) | Chemical compounds | |
| NZ706999A (en) | Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof | |
| NZ576425A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors | |
| MX2015011504A (es) | Inhibidores de ras y sus usos. | |
| RU2018145048A (ru) | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк | |
| WO2014152389A8 (en) | Imaging agent for detection of diseased cells | |
| MY170904A (en) | Ret inhibitor | |
| BR112018072872A2 (pt) | compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indol para tratar câncer | |
| JP2016533366A5 (enExample) | ||
| HK1203927A1 (en) | Heterocyclic compounds and uses as anticancer agents | |
| MY156210A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| PE20170384A1 (es) | Compuesto piridinicos de planieolida y metodos de uso | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| WO2014130410A8 (en) | Dppf-like compounds and methods |